Using Alternative Medicine Alone Has Major Risks

A recent study on alternative medicine and cancer out of the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale School of Medicine and Yale Cancer Center, suggests that cancer patients who opt out of conventional therapy (chemotherapy, radiation, immunotherapy, surgery, for example),…

Read Full Post

FDA Approves First Biosimilar to Treat Cancer

Mvasi (bevacizumab-awwb; ABP-215) is a biologic product that was recently approved by the FDA to treat colorectal and other cancers. What are biosimilars and who is a candidate for Mvasi? Biosimilars are the new kid on the block In 2015, we wrote a blog about…

Read Full Post

Methylated Septin9: Blood Test to Detect Colorectal Cancer

There are many patients who are resistant to colonoscopy, and the good news is, there are currently screening tests that have been approved by the Federal Drug Administration (FDA) and recommended by the United States Preventive Services Task Force (USPSTF). These are tests designed for…

Read Full Post

Rice Bran and Beans for CRC

Nutrition is a hot topic in the world of cancer research and cancer survivorship, and rightly so! What we put into our bodies greatly affects our overall health and wellness. In terms of cancer, many studies show that eating a diet low in red meat…

Read Full Post
Reese Garcia

Dedicated to Research

Meet Reese Garcia, our new Research Advocacy Manager, and see why and how she developed a passion for research and fighting for those with colorectal cancer. My CRC Connection One semester into my public health graduate studies back in 2016, I stumbled into a research…

Read Full Post

Fight CRC Partners on 2017 NCCN Guidelines for Patients

[SPRINGFIELD, MO — August 11, 2017] Fight Colorectal Cancer is the proud advocacy partner of the NCCN Foundation® for the publication of the 2017 versions of the NCCN Guidelines for Patients® for Colon and Rectal Cancers. These patient resources are published by the National Comprehensive…

Read Full Post
Breaking Research News

FDA approves Opdivo for MSI-H or dMMR Metastatic Colorectal Cancer

On August 1, 2017, the FDA approved the use of Opdivo (nivolumab) in microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). This is very exciting for the colorectal cancer community, who has seen a push in research efforts and immunotherapy…

Read Full Post

Surviving Colorectal Cancer

It may sound surprising to some, but not all cancer research focuses on finding a treatment to cure a disease. In fact, research efforts are well underway in the realm of cancer survivorship, including continued support for physical, mental, and emotional health of cancer patients….

Read Full Post
Page 1 of 11612345...102030...Last »